PODD Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 1.06%, SMA50 -6.94%, SMA200 -17.29%). The stock’s 14-day RSI is 46.09 (neutral), while the ATR of 9.77 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -29.13% below its high and over 9.32% above its low. Average 10-day trading volume of 1.55 million shares is slightly above the 3-month average of 1.39 million, indicating heightened recent market interest.

Insulet Corp. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $23.37. This means the shares are trading above this model’s fair value.

Insulet Corporation has 70.39 million shares outstanding. The public float is 70.08 million shares, elevated short interest at 3.79% of float. This equals 1.75 million shares. The short ratio is 3.03 days. Institutional investors hold 105.88% of the float. Insiders own 0.33%. Levitz Michael L holds 56.65 thousand shares, Alpuche Charles has 45.58 thousand shares and Hollingshead James has 34.18 thousand shares. Over the past six months, insider transactions show net buying. They sold 418.00 shares across 1 transactions.

Insulet Corp. (NASDAQ:PODD) closed at $143.90 USD, gaining $4.93 (3.55%) from the previous close of $138.97. The stock is currently within 5% of its 52-week low $138.79 and $354.88. With a market capitalization of about $9.97 billion, Insulet Corp. is classified as a mid-cap and shows higher-than-market volatility (beta ~1.43). Key stats such as the average daily volume over the past year has been around 1.39 million shares, in line with its 52-week average. Headquartered in Acton, MA, Insulet Corp. operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Ashley A. McEvoy, the company employs approximately 5,400 people and listed since May 17, 2007. Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally.

Insulet Corporation generated EPS of $3.50 over the past year. Five-year average earnings growth is 102.14%. Wall Street analysts project EPS growth of 27.09% annually over the next five years. The latest quarter delivered EPS of $1.42. The next quarter is forecast at $1.20. Next year's EPS is expected at $26.23. Analyst sentiment is bullish. Analyst rating data shows there are 20 Strong Buy ratings, 29 Buy ratings, 7 Hold ratings, 0 Sell rating and 2 Strong Sell ratings. Price targets range from $450.00 to $165.00. The high target offers 223.81% upside. The low target suggests 18.73% downside. The mean target is $327.36. This offers 135.56% upside. Insulet Corporation earnings surprise history is a consistent trend of beating forecasts. The quarter that ended May 06, 2026, missed forecasts by 19.33%. The prior quarter beat by 5.44%. Over the last six quarters, Apple has recorded several small beats. These include 15.0% in February 20, 2025.

Insulet Corporation trades at a P/E ratio of 33.51, slightly above the S&P 500 average, with a price-to-sales ratio of 3.45 and a price-to-book ratio of 7.76 trading at moderately above to book value. The P/FCF stands at 24.27, also above market averages.

Insulet Corporation (NASDAQ:PODD) shares are flat 0.0% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Insulet Corporation trading at a premium to the broader market with a P/E of 33.51. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $301.93, suggesting 117.26% upside. Our AI forecast model points to short-term weakness (-1.73% over two weeks), a medium-term rise (8.48% over three months), and a longer-term gain (8.9% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Insulet Corporation stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -1.73%, with price expected at $136.57 by July 06, 2026, within a range of $131.21 to $141.49 3-Month Outlook: Projected rise of 8.48%, reaching $150.76 by September 18, 2026, with a range of $136.65 to $160.72. 1-Year Outlook: Projected gain of 8.9%, with price at $151.34 by June 22, 2027, within a range of $125.70 to $170.30.